

Editorial Policy

To enable deeper stakeholder understanding of Astellas' efforts to continue to create value for sustainable growth, the Company has published this annual report as an integrated report.

In this report, we have attempted to provide disclosure while taking note of the Guiding Principles and Content Elements of the international integrated reporting framework of the International Integrated Reporting Council (IIRC). We have also referred to G4 Sustainability Reporting Guidelines* published by the Global Reporting Initiative and Environmental Reporting Guidelines (Fiscal Year 2012 Version) issued by Japan's Ministry of the Environment.

In creating the report, we have sought to make an effective tool for communicating with our many stakeholders. We have therefore used charts and photographs, and endeavored to use plain language that is easy to read.

Astellas has adopted the International Financial Reporting Standards (IFRS), effective from fiscal 2013. Information in this report is based on IFRS unless otherwise indicated.

* For the GRI Content Index, please visit the following website:
<https://www.astellas.com/en/csr/management/report.html>

Scope of the Report

Period covered

Fiscal 2015 (April 1, 2015 - March 31, 2016)

- * As much as possible, we have used the latest information available at the time of publication.
- * The period and scope of coverage may vary depending on the subject. We have noted each such case individually.
- * The figures indicated in the field of Environment represent the results for fiscal 2015 (April 1, 2015 to March 31, 2016) in Japan and the calendar year 2015 (January 1 to December 31, 2015) for overseas operations as a combined total.

Organizations covered

Astellas Pharma Inc. and its consolidated subsidiaries in Japan and overseas (referred to in the report as "Astellas")

- * The Americas includes North America and Latin America, and EMEA includes Europe, the Middle East, and Africa.
- * In the field of Environment, the report covers all business sites in Japan and production sites overseas, which are subject to the Environmental Action Plan, as well as overseas sites not covered by the plan such as principal office buildings, research facilities, sales office buildings, and sales fleets.

Note: In the information about pharmaceutical products in this report, market size, market share and product ranking are sourced from IMS Health Information Services.

©2015 IMS Health
 Calculated based on IMS MIDAS 2016Q1 MAT
 Reprinted with permission

Websites

Corporate Website



<http://www.astellas.com/en/>

Investor Relations



<http://www.astellas.com/en/ir/>

Social Responsibility



<http://www.astellas.com/en/csr/>